These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

752 related articles for article (PubMed ID: 15753357)

  • 21. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features.
    Finberg KE; Sequist LV; Joshi VA; Muzikansky A; Miller JM; Han M; Beheshti J; Chirieac LR; Mark EJ; Iafrate AJ
    J Mol Diagn; 2007 Jul; 9(3):320-6. PubMed ID: 17591931
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation.
    Blons H; Côté JF; Le Corre D; Riquet M; Fabre-Guilevin E; Laurent-Puig P; Danel C
    Am J Surg Pathol; 2006 Oct; 30(10):1309-15. PubMed ID: 17001163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma.
    Haneda H; Sasaki H; Lindeman N; Kawano O; Endo K; Suzuki E; Shimizu S; Yukiue H; Kobayashi Y; Yano M; Fujii Y
    Jpn J Clin Oncol; 2006 Feb; 36(2):69-75. PubMed ID: 16449241
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation.
    Suda K; Tomizawa K; Mitsudomi T
    Cancer Metastasis Rev; 2010 Mar; 29(1):49-60. PubMed ID: 20108024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidermal growth factor receptor mutations in lung cancers.
    Yatabe Y; Mitsudomi T
    Pathol Int; 2007 May; 57(5):233-44. PubMed ID: 17493170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytomorphological correlates of epidermal growth factor receptor mutations in lung carcinoma.
    Brachtel EF; Iafrate AJ; Mark EJ; Deshpande V
    Diagn Cytopathol; 2007 May; 35(5):257-62. PubMed ID: 17427221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
    Chou TY; Chiu CH; Li LH; Hsiao CY; Tzen CY; Chang KT; Chen YM; Perng RP; Tsai SF; Tsai CM
    Clin Cancer Res; 2005 May; 11(10):3750-7. PubMed ID: 15897572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma.
    Bonanno L; Schiavon M; Nardo G; Bertorelle R; Bonaldi L; Galligioni A; Indraccolo S; Pasello G; Rea F; Favaretto A
    Anticancer Res; 2010 Dec; 30(12):5121-8. PubMed ID: 21187500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
    Ohtsuka K; Ohnishi H; Fujiwara M; Kishino T; Matsushima S; Furuyashiki G; Takei H; Koshiishi Y; Goya T; Watanabe T
    Cancer; 2007 Feb; 109(4):741-50. PubMed ID: 17238183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ERBB2 kinase domain mutation in the lung squamous cell carcinoma.
    Lee JW; Soung YH; Kim SY; Nam SW; Park WS; Wang YP; Jo KH; Moon SW; Song SY; Lee JY; Yoo NJ; Lee SH
    Cancer Lett; 2006 Jun; 237(1):89-94. PubMed ID: 16029927
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.
    Mitsudomi T; Steinberg SM; Nau MM; Carbone D; D'Amico D; Bodner S; Oie HK; Linnoila RI; Mulshine JL; Minna JD
    Oncogene; 1992 Jan; 7(1):171-80. PubMed ID: 1311061
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.
    Shigematsu H; Lin L; Takahashi T; Nomura M; Suzuki M; Wistuba II; Fong KM; Lee H; Toyooka S; Shimizu N; Fujisawa T; Feng Z; Roth JA; Herz J; Minna JD; Gazdar AF
    J Natl Cancer Inst; 2005 Mar; 97(5):339-46. PubMed ID: 15741570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas.
    Lee JW; Soung YH; Seo SH; Kim SY; Park CH; Wang YP; Park K; Nam SW; Park WS; Kim SH; Lee JY; Yoo NJ; Lee SH
    Clin Cancer Res; 2006 Jan; 12(1):57-61. PubMed ID: 16397024
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers.
    Tomizawa K; Suda K; Onozato R; Kosaka T; Endoh H; Sekido Y; Shigematsu H; Kuwano H; Yatabe Y; Mitsudomi T
    Lung Cancer; 2011 Oct; 74(1):139-44. PubMed ID: 21353324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The presence of HER2 exon 20 insertion in patients with central nervous system metastases from non-small lung cancer--a potential application in classification for therapy.
    Nicoś M; Krawczyk P; Mlak R; Sawicki M; Jarosz B; Powrózek T; Milanowski P; Trojanowski T; Milanowski J
    Pneumonol Alergol Pol; 2013; 81(4):294-7. PubMed ID: 23744164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer.
    Kobayashi M; Sonobe M; Takahashi T; Yoshizawa A; Ishikawa M; Kikuchi R; Okubo K; Huang CL; Date H
    Anticancer Res; 2011 Dec; 31(12):4619-23. PubMed ID: 22199339
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EGFR and erbB2 mutation status in Japanese lung cancer patients.
    Sasaki H; Shimizu S; Endo K; Takada M; Kawahara M; Tanaka H; Matsumura A; Iuchi K; Haneda H; Suzuki E; Kobayashi Y; Yano M; Fujii Y
    Int J Cancer; 2006 Jan; 118(1):180-4. PubMed ID: 16003726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutation and polymorphism in the EGFR-TK domain associated with lung cancer.
    Zhang W; Stabile LP; Keohavong P; Romkes M; Grandis JR; Traynor AM; Siegfried JM
    J Thorac Oncol; 2006 Sep; 1(7):635-47. PubMed ID: 17409930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histopathologic characteristics of pulmonary adenocarcinomas with and without EGFR mutation.
    Chantranuwat C; Sriuranpong V; Huapai N; Chalermchai T; Leungtaweeboon K; Voravud N; Mutirangura A
    J Med Assoc Thai; 2005 Sep; 88 Suppl 4():S322-9. PubMed ID: 16623049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ErbB4 expression and mutation in Japanese patients with lung cancer.
    Sasaki H; Okuda K; Kawano O; Endo K; Yukiue H; Yokoyama T; Yano M; Fujii Y
    Clin Lung Cancer; 2007 Jul; 8(7):429-33. PubMed ID: 17681096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.